Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Awakn Life Sciences Corp
C.AWKN
Alternate Symbol(s):
AWKNF
Healthcare
Biotechnology
Awakn Life Sciences Corp. is a Canada-based clinical-stage biotechnology company. The Company is developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company...
operates through three segments: development, delivery and corporate. The development segment, which focuses on researching and developing psychedelic drugs and therapies, ketamine-assisted psychotherapy and methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy to treat substance and behavioral addictions. The delivery segment, which includes a chain of medical psychedelic clinics across Europe and through licensing partners. The Company operates in Ireland and Canada. The Company’s development pipeline includes AWKN-001, AWKN-002 and MDMA.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (CSE:AWKN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(282)
•••
TheBridge
X
Post by
TheBridge
on Nov 27, 2024 2:55pm
Waiting
Once this tax loss season is over we just might see this share price Awakin and start moving up. But as everyone knows these biotechs are a risky buiness and take a lot of time to determine whether
...more
(1)
•••
Badger66
X
Post by
Badger66
on Sep 26, 2023 9:40am
Stifel - "‘Favourable Commercialization Outcome" PT C$1.75
Analysts at Stifel GMP expect a “favourable commercialization outcome” from Awakn Life Sciences Corp (NEO:AWKN)’s planned Phase 3 trial of novel ketamine drug AWKN-P001 in combination with
...more
Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents
posted Dec 03, 2024 9:00am by
Revive Therapeutics Ltd
-
|
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more
(92)
•••
doggy123
X
Comment by
doggy123
on Jun 13, 2023 9:17am
RE:RE:RE:RE:RE:RE:Seem
Unreal why scientists,doctors insiders in this company don't buy at market at this ridiculous price
(92)
•••
doggy123
X
Comment by
doggy123
on Jun 09, 2023 9:24am
RE:RE:RE:RE:RE:Seem
Halted..........
(92)
•••
doggy123
X
Comment by
doggy123
on Jun 05, 2023 11:00am
RE:RE:RE:RE:Seem
Q1 should be out pretty soon.......
(92)
•••
doggy123
X
Comment by
doggy123
on May 12, 2023 9:18am
RE:RE:RE:Seem
This new company is a sleeping giant to a world of giant wide problem addictions.......Potential is so high with no interest yet.......watch it it's coming ....$$$
(92)
•••
doggy123
X
Comment by
doggy123
on May 04, 2023 9:51am
RE:RE:Seem
Man i would like some comments on this stock.............level 2 is crazy so thin that with some good news this thing could pop up $2.00 plus $3.00 dollars almost instantly.......why some sell now is
...more
(92)
•••
doggy123
X
Comment by
doggy123
on May 01, 2023 7:50pm
RE:Seem
Do your own dd.........Analyst Price target $1.75 buying recommendation rating by Yahoo
(92)
•••
doggy123
X
Post by
doggy123
on May 01, 2023 2:04pm
Seem
Seem a very big potential here with AWKN short future
(3217)
•••
Betteryear2
X
Post by
Betteryear2
on Aug 10, 2022 5:22pm
Microdose Announces The 2nd Annual Microdose Awards
Miami, Florida--(Newsfile Corp. - August 9, 2022) - Microdose Psychedelic Insights, the leading guide to the business of psychedelics, is excited to announce the lineup of categories for the 2nd
...more
(37)
•••
BryceCanada
X
Post by
BryceCanada
on Jul 25, 2022 5:11pm
Big news from AWKN!
https://youtu.be/lPV2X3I_0Gk
(0)
•••
BullishPicks
X
Post by
BullishPicks
on Jun 15, 2022 10:58am
AWKN Featured News 6/15/22: Pioneering Psychedelic Therapies
Awakn Life Sciences Corp (OTCQB:AWKNF/ NEO:AWKN) Pioneering Psychedelic Therapies to treat AUD https://stockifymedia.com/awakn-life-sciences-corp-otcqbawknf-neoawkn-pioneering-psychedelic-therapies
...more
(37)
•••
BryceCanada
X
Post by
BryceCanada
on Apr 28, 2022 5:02pm
New CEO discussion from AWKN
https://youtu.be/lUQiFawTyNg
(37)
•••
BryceCanada
X
Post by
BryceCanada
on Apr 13, 2022 6:23pm
Excellent YT analysis on AWKN
https://youtu.be/123f1mNpt-Q
(2)
•••
@EquityInsight
X
Post by
@EquityInsight
on Apr 13, 2022 10:39am
Awakn Life Sciences Receives $8.00 Price Target!
Prominent Investment banking firm Stifel GMP has recently published an analyst report issuing a BUY for Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) with a price target of $8.00. To Read
...more
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
Featured News Links
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth